Natalizumab for 2nd Line Treatment in Relapsing-Remitting Multiple Sclerosis Patients- 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.2240
https://www.valueinhealthjournal.com/article/S1098-3015(13)04152-1/fulltext
Section Title :
Disease-Specific Studies
Section Order :
2054
First Page :
A720
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)04152-1&doi=10.1016/j.jval.2013.08.2240